Adrenomedullin in Context With Pulmonary Embolism

Plain-language summary

This study aims to examine a marker called adrenomedullin, using blood samples, in patients with acute pulmonary embolism. It enrolled patients aged 18 and older with imaging-confirmed intermediate-high and high-risk acute pulmonary embolism. It was a non-phased study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University of Pecs

Intervention

blood samples

Start date

8/19/2020

Estimated completion

5/8/2023

Countries

Austria, Hungary

Related genes

Locations

• Oberwart, Austria
• Pécs, Hungary

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients with intermediate high and high risk of an acute pulmonary embolism with clinical symptoms.
* On image based procedures confirmed pulmonary embolism (TTE, contrast CT-angiography).
* Written agreement to the examination.

Exclusion Criteria:

* Age under 18.
* Missing written agreement or cancelled agreement on any time.